ClinicalTrials.gg
CompletedNCT00943722Updated Oct 3, 2022Results posted

A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)

A Phase 3 interventional study of V503 in Cervical Cancers, Vulvar Cancer and Vaginal Cancer, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 9 Years to 26 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-03.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,074
Allocation
Randomized
Ages
9 Years to 26 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 14 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Uterine Cervical Neoplasms — 6 open to participants now, 8 under way, 3 of them phase 3. Human Papillomavirus Recombinant Vaccine nonavalent · Uterine Cervical Neoplasms.

Enrollment
3rd of 14
3,074 · median 1,206
Started
2009
the only one that year
Phase 3
9 of 14
2 open now
Registered
1st of 14
by date
Lead sponsor
5 of 14
Merck Sharp & Dohme LLC

Among the 14 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Uterine Cervical Neoplasms, this one is the 3rd largest by enrollment, is the only one that started in 2009, is one of 9 in phase 3, and was the 1st registered.

Uterine Cervical Neoplasms

2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

6 of the 14 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Uterine Cervical Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About Human Papillomavirus Recombinant Vaccine nonavalent

Human Papillomavirus Recombinant Vaccine nonavalent: first FDA approval 2014 (Gardasil 9). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 474 Uterine Cervical Neoplasms studies recruiting now, 244 (51%) set no upper age limit and 190 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 9 Years to 26 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Uterine Cervical Neoplasms, or all of them as a file.
02

Study summary

This study will evaluate the immunogenicity and tolerability of V503 (a multivalent human papillomavirus [HPV] L1 virus-like particle [VLP] vaccine) in preadolescent and adolescent participants between 9 and 15 years old and demonstrate the consistency of the manufactured vaccine through assessment of 3 different final manufacturing process lots of V503.

The primary hypotheses are as follows:

  1. The 9-valent HPV L1 VLP vaccine when administered to preadolescent and adolescent boys and girls 9 to 15 years of age and young women 16 to 26 years of age is generally well-tolerated.
  2. 9-valent HPV L1 VLP vaccine induces non-inferior immune responses in preadolescent and adolescent girls 9 to 15 years of age who are seronegative at Day 1 to the relevant HPV type compared to young women 16 to 26 years of age who are seronegative at Day 1 and polymerase chain reaction (PCR)-negative Day 1 through Month 7 to the relevant HPV type, as measured by anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 geometric mean titers (GMTs) at 4 weeks post-dose 3.
  3. The 9-valent HPV L1 VLP vaccine induces non-inferior immune responses in preadolescent and adolescent boys 9 to 15 years of age who are seronegative at Day 1 to the relevant HPV type compared to young women 16 to 26 years of age who are seronegative at Day 1 and PCR-negative Day 1 through Month 7 to the relevant HPV type, as measured by anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 GMTs at 4 weeks post-dose 3.
  4. Three separate final manufacturing process (FMP) lots of the 9-valent HPV L1 VLP vaccine induce similar immune responses, as measured by anti-HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 GMTs at 4 weeks post-dose 3.
Read the detailed description

The base study V503-002 was a 12-month study that collected immunogenicity data through Month 7 and safety data through Month 12.

An optional extension study (V503-002 EXT1) collected safety and immunogenicity information through Month 36. Participants enrolled in the 16- to 26-year-old cohort in the base study were not included in EXT1. Per protocol, EXT1 included immunogenicity data from a subset of 9- to 15-year-old females and safety data from all 9- to 15-year-old females regardless of lot administered.

An optional second extension study (V503-002 EXT2) collected long-term safety and immunogenicity information through approximately Month 126. No study vaccine was administered in the extension studies. Participants enrolled in the 16- to 26-year-old cohort in the base study were not included in EXT2. Per protocol, EXT2 included immunogenicity data from a subset of 9- to 15-year-old females and effectiveness and safety data from all 9- to 15-year-old females regardless of lot administered.

03

Conditions studied

  • Cervical Cancers
  • Vulvar Cancer
  • Vaginal Cancer
  • Genital Lesions
  • PAP Test Abnormalities
  • HPV Infections
04

Who can participate

Ages eligible
9 Years to 26 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Boys and Girls Age 9 to 15:

  • Participant has not had sexual intercourse prior to the study and does not plan to become sexually active during the study period Day 1 to Month 7

Women Age 16 to 26:

  • Participant has never had Pap testing or has had only normal results
  • Participant has had 0 to 4 sexual partners at the time of enrollment

Exclusion criteria

Exclusion Criteria:

Boys and Girls Age 9 to 15:

  • History of allergic reaction that required medical intervention
  • Currently enrolled in any other clinical study
  • Participant is pregnant
  • Participant is or has taken immunosuppressants in the last year
  • Participant has received a marketed HPV vaccine or participated in an HPV vaccine clinical trial
  • Participant has a history of positive test for HPV

Women Age 16 to 26:

  • History of allergic reaction that required medical intervention
  • Currently enrolled in any other clinical study
  • Participant is pregnant
  • Participant is immunocompromised or has taken immunosuppressants in the last year
  • Participant has received a marketed HPV vaccine or participated in an HPV vaccine clinical trial
  • Participant has a history of positive test for HPV
  • Participant has a history of abnormal cervical result
  • Participant has a history of external genital lesions
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3,074 participants (actual)

Study arms

  • Experimental
    9- to 15-Year-Old Females (Lot 1)

    9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 1.

    Biological: V503

  • Experimental
    9- to 15-Year-Old Females (Lot 2)

    9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 2.

    Biological: V503

  • Experimental
    9- to 15-Year-Old Females (Lot 3)

    9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 3.

    Biological: V503

  • Experimental
    9- to 15-Year-Old Males (Lot 1)

    9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 1.

    Biological: V503

  • Experimental
    16- to 26-Year-Old Females (Lot 1)

    9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 1.

    Biological: V503

Interventions

  • BiologicalV503

    Multivalent HPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lots 1, 2, or 3.

06

What researchers measure

Primary outcomes

  1. Base Study: Geometric Mean Titers (GMTs) for Each of the HPV Types Contained in the Vaccine (9- to 15-Year-Old Females [Lot 1] and 16- to 26-Year-Old Females [Lot 1])

    Serum antibody titers for HPV virus-like particles (VLPs), Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using a competitive luminex immunoassay (cLIA). Titers were reported in milli Merck Units/mL.

    Time frame: 4 weeks post-vaccination 3 (Month 7)

  2. Base Study: GMTs for Each of the HPV Types Contained in the Vaccine (9- to 15-Year-Old Males [Lot 1] and 16- to 26-Year-Old Females [Lot 1])

    Serum antibody titers for HPV VLPs, Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using a competitive luminex immunoassay (cLIA). Titers were reported in milli Merck Units/mL.

    Time frame: 4 weeks post-vaccination 3 (Month 7)

  3. Base Study: GMTs for Each of the HPV Types Contained in the Vaccine (Lot Consistency Study)

    Serum antibody titers for HPV VLPs, Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using cLIA. Titers were reported in milli Merck Units/mL.

    Time frame: 4 weeks post-vaccination 3 (Month 7)

  4. Base Study: Percentage of Participants With Injection Site Adverse Experiences (AEs)

    An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine was also an AE. AEs such as redness, swelling, and pain/tenderness/soreness at the injection site were recorded.

    Time frame: Up to 5 days after any vaccination

  5. Base Study: Percentage of Participants With Systemic AEs

    An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine was also an AE. Systemic AEs were those not categorized as injection-site AEs.

    Time frame: Up to 15 days after any vaccination

  6. Base Study: Percentage of Participants With Body Temperature ≥100.0°F (≥37.8ºC)

    Participants collected their oral body temperature in the evening of their vaccination day and at the same time each day thereafter for 4 days. The maximum body temperature obtained within 5 days of any of the 3 vaccinations was recorded. The percentage of participants who had at least 1 oral body temperature reading that was ≥100.0°F (≥37.8ºC) was summarized.

    Time frame: Up to 5 days after any vaccination

  7. Extension Study: GMTs For Each of the HPV Types Contained in the Vaccine

    Serum antibody titers (milli Merck Units/mL) measured by cLIA to each of the 9vHPV types were assessed. Per protocol, the extension study included data from 9- to 15-year-old females regardless of lot administered.

    Time frame: Up to ~Month 126

  8. Extension Study: Percentage of Participants Who Are Seropositive to Each of the HPV Types Contained in the Vaccine

    Serum antibody titers for HPV VLPs Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined and reported in milli Merck Units/mL. The percentage of participants seropositive to each HPV type was reported. Per protocol, the extension study included data from 9- to 15-year-old females regardless of lot administered.

    Time frame: Up to ~Month 126

Secondary outcomes

  1. Base Study: Percentage of Participants Who Seroconvert to Each of the HPV Types Contained in the Vaccine (9- to 15-Year-Old Females [Lot 1] and 16- to 26-Year-Old Females [Lot 1])

    Serum antibody titers for HPV virus-like particles (VLPs), Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using cLIA. The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30, HPV Type 11: ≥16; HPV Type 16: ≥20, HPV Type 18: ≥24, HPV Type 31: ≥10, HPV Type 33: ≥8, HPV Type 45: ≥8, HPV Type 52: ≥8, and HPV Type 58: ≥8.

    Time frame: 4 weeks post-vaccination 3 (Month 7)

  2. Base Study: Percentage of Participants Who Seroconvert to Each of the HPV Types Contained in the Vaccine (9- to 15-Year-Old Males [Lot 1] Versus 16- to 26-Year-Old Females [Lot 1])

    Serum antibody titers for HPV VLPs, Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using cLIA. The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30, HPV Type 11: ≥16; HPV Type 16: ≥20, HPV Type 18: ≥24, HPV Type 31: ≥10, HPV Type 33: ≥8, HPV Type 45: ≥8, HPV Type 52: ≥8, and HPV Type 58: ≥8.

    Time frame: 4 weeks post-vaccination 3 (Month 7)

  3. Base Study: Percentage of Participants Who Seroconvert to Each of the HPV Types Contained in the Vaccine (Lot Consistency Study)

    Serum antibody titers for HPV virus-like particles (VLPs), Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post- vaccination 3 using cLIA. The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30, HPV Type 11: ≥16; HPV Type 16: ≥20, HPV Type 18: ≥24, HPV Type 31: ≥10, HPV Type 33: ≥8, HPV Type 45: ≥8, HPV Type 52: ≥8, and HPV Type 58: ≥8.

    Time frame: 4 weeks post-vaccination 3 (Month 7)

  4. Extension Study: Combined Incidence of HPV 6/11/16/18/31/33/45/52/58-Related Persistent Infection in Females

    Persistent infection is when a participant is positive by polymerase chain reaction (PCR) for the same HPV type in cervicovaginal/external genital swabs or tissue specimens collected at consecutive visits at least 6 months (+/-1 month visit window) apart. Incidence was estimated as cases per 10,000 person-years. Person-years follow-up was from beginning of long-term follow-up or when a study participant reached 16 years of age, whichever came later. Per protocol, the extension study included 9- to 15-year-old females regardless of lot administered.

    Time frame: Up to ~Month 126

  5. Extension Study: Combined Incidence of HPV 6/11/16/18/31/33/45/52/58-Related Persistent Infection in Males

    Persistent infection is when a participant is positive by PCR for the same HPV type in external genital swabs or tissue specimens collected at consecutive visits at least 6 months (+/-1 month visit window) apart. Incidence was estimated as cases per 10,000 person-years. Person-years follow-up was from beginning of long-term follow-up or when a study participant reached 16 years of age, whichever came later.

    Time frame: Up to ~Month 126

  6. Extension Study: Combined Incidence of Cervical Intraepithelial Neoplasia, Vulvar Intraepithelial Neoplasia, Vaginal Intraepithelial Neoplasia, Genital Warts, and Cervical/Vulvar/Vaginal Cancers Related to HPV 6/11/16/18/31/33/45/52/58 in Females

    The combined incidence of cervical intraepithelial neoplasia, vulvar intraepithelial neoplasia, vaginal intraepithelial neoplasia, genital warts, and cervical/vulvar/vaginal cancers, related to HPV 6/11/16/18/31/33/45/52/58 was assessed. This outcome measure was determined by clinical/pathologic criteria and positive PCR assay for HPV type. Incidence was estimated as cases per 10,000 person-years. Person-years follow-up was calculated starting from the beginning of the long-term follow-up study or the date when the study participant reached 16 years of age, whichever came later. Per protocol, the extension study included data from 9- to 15-year-old females regardless of lot administered.

    Time frame: Up to ~Month 126

  7. Extension Study: Combined Incidence of Penile Intraepithelial Neoplasia, Penile/Perineal/Perianal Cancers and Genital Warts Related to HPV 6/11/16/18/31/33/45/52/58 in Males

    The combined incidence of penile intraepithelial neoplasia, penile/perineal/perianal cancers, and genital warts related to HPV6/11/16/18/31/33/45/52/58 was assessed. This outcome measure was determined by clinical/pathologic criteria and positive PCR assay for HPV type. Incidence was estimated as cases per 10,000 person-years. For each study participant, person-years follow up was calculated starting from the beginning of the long-term follow-up study or the date when the study participant reached 16 years of age, whichever came later.

    Time frame: Up to ~Month 126

  8. Extension Study: Percentage of Participants With Vaccine-Related or Procedure-Related Serious Adverse Events

    A serious adverse event (SAE) included a death which resulted in the participant discontinuing the study, a serious adverse experience that was considered by an investigator who was a qualified physician to be possibly, probably, or definitely vaccine related or study procedure related. Per protocol, the extension study included data from 9- to 15-year-old females regardless of lot administered.

    Time frame: Up to ~Month 126

07

Results

Posted Jan 13, 2015

Participant flow

The base study was a 12-month study that collected immunogenicity data through Month 7 and safety data through Month 12.

Base Study
Participant flow — Base Study
MilestoneBase Study: 9- to 15-Year-Old Females (Lot 1)Base Study: 9- to 15-Year-Old Females (Lot 2)Base Study: 9- to 15-Year-Old Females (Lot 3)Base Study: 9- to 15-Year-Old Males (Lot 1)Base Study: 16- to 26-Year-Old Females (Lot 1)Extension Study: 9- to 15-Year-Old FemalesExtension Study: 9- to 15-Year-Old Males
Started64864364466947000
Vaccination 164664264466646800
Vaccination 263763363865846200
Vaccination 363562763765345500
At least one dose with protocol-specified safety follow-up64363964166246600
Completed62362163164744400
Not completed252213222600
Withdrew: Adverse event0001000
Withdrew: Lost to follow-up1281081100
Withdrew: Physician decision1000100
Withdrew: Pregnancy0010200
Withdrew: Protocol violation0100200
Withdrew: Withdrawal by subject1213213800
Withdrew: Month 12 visit not completed0000200
First Extension Study: EXT 1
Participant flow — First Extension Study: EXT 1
MilestoneBase Study: 9- to 15-Year-Old Females (Lot 1)Base Study: 9- to 15-Year-Old Females (Lot 2)Base Study: 9- to 15-Year-Old Females (Lot 3)Base Study: 9- to 15-Year-Old Males (Lot 1)Base Study: 16- to 26-Year-Old Females (Lot 1)Extension Study: 9- to 15-Year-Old FemalesExtension Study: 9- to 15-Year-Old Males
Started000001604568
Completed000001489527
Not completed0000011541
Withdrew: Adverse event0000010
Withdrew: Lost to follow-up000003810
Withdrew: Withdrawal by subject000003210
Withdrew: Disposition unknown000004421
Second Extension Study: EXT 2
Participant flow — Second Extension Study: EXT 2
MilestoneBase Study: 9- to 15-Year-Old Females (Lot 1)Base Study: 9- to 15-Year-Old Females (Lot 2)Base Study: 9- to 15-Year-Old Females (Lot 3)Base Study: 9- to 15-Year-Old Males (Lot 1)Base Study: 16- to 26-Year-Old Females (Lot 1)Extension Study: 9- to 15-Year-Old FemalesExtension Study: 9- to 15-Year-Old Males
Started00000971301
Completed00000720202
Not completed0000025199
Withdrew: Adverse event0000010
Withdrew: Lost to follow-up0000011146
Withdrew: Physician decision0000013
Withdrew: Pregnancy0000010
Withdrew: Withdrawal by subject0000013750

Outcome measures

PrimaryBase Study: Geometric Mean Titers (GMTs) for Each of the HPV Types Contained in the Vaccine (9- to 15-Year-Old Females [Lot 1] and 16- to 26-Year-Old Females [Lot 1])

Serum antibody titers for HPV virus-like particles (VLPs), Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using a competitive luminex immunoassay (cLIA). Titers were reported in milli Merck Units/mL.

Time frame:
4 weeks post-vaccination 3 (Month 7)
Reported as:
Geometric mean · milli Merck Units/mL
Base Study: Geometric Mean Titers (GMTs) for Each of the HPV Types Contained in the Vaccine (9- to 15-Year-Old Females [Lot 1] and 16- to 26-Year-Old Females [Lot 1])
milli Merck Units/mLBase Study: 9- to 15-Year-Old Females (Lot 1)Base Study: 9- to 15-Year-Old Males (Lot 1)
Anti-HPV 61715.4 (1595.1 to 1844.7)900.8 (822.3 to 986.9)
Anti-HPV 111295.1 (1204.1 to 1393.0)706.6 (645.2 to 773.8)
Anti-HPV 166979.8 (6508.1 to 7485.8)3522.6 (3223.5 to 3849.5)
Anti-HPV 182153.7 (1980.4 to 2342.1)882.7 (795.4 to 979.5)
Anti-HPV 311891.6 (1745.7 to 2049.7)753.9 (682.5 to 832.7)
Anti-HPV 33980.4 (911.7 to 1054.3)466.8 (426.9 to 510.3)
Anti-HPV 45714.4 (651.9 to 782.8)272.2 (243.8 to 303.9)
Anti-HPV 52932.9 (864.8 to 1006.4)419.6 (381.4 to 461.5)
Anti-HPV 581286.7 (1195.7 to 1384.6)590.5 (538.2 to 647.9)
Statistical analysis
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Males (Lot 1) · ANOVA · p = < 0.001 (one-sided tests of non-inferiority conducted at the alpha=0.025 level; model with a response of log individual titers and a fixed effect for comparison group) · Gmt ratio: 1.90 · 95% CI 1.70 to 2.14GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 16- to 26-Year-Old Females (Lot 1)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Males (Lot 1) · ANOVA · p = < 0.001 (one-sided tests of non-inferiority conducted at the alpha=0.025 level; model with a response of log individual titers and a fixed effect for comparison group) · Gmt ratio: 1.83 · 95% CI 1.63 to 2.06GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 16- to 26-Year-Old Females (Lot 1)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Males (Lot 1) · ANOVA · p = < 0.001 (one-sided tests of non-inferiority conducted at the alpha=0.025 level; model with a response of log individual titers and a fixed effect for comparison group) · Gmt ratio: 1.98 · 95% CI 1.77 to 2.22GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 16- to 26-Year-Old Females (Lot 1)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Males (Lot 1) · ANOVA · p = < 0.001 (one-sided tests of non-inferiority conducted at the alpha=0.025 level; model with a response of log individual titers and a fixed effect for comparison group) · Gmt ratio: 2.44 · 95% CI 2.13 to 2.80GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 16- to 26-Year-Old Females (Lot 1)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Males (Lot 1) · ANOVA · p = < 0.001 (one-sided tests of non-inferiority conducted at the alpha=0.025 level; model with a response of log individual titers and a fixed effect for comparison group) · Gmt ratio: 2.51 · 95% CI 2.21 to 2.85GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 16- to 26-Year-Old Females (Lot 1)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Males (Lot 1) · ANOVA · p = < 0.001 (one-sided tests of non-inferiority conducted at the alpha=0.025 level; model with a response of log individual titers and a fixed effect for comparison group) · Gmt ratio: 2.10 · 95% CI 1.87 to 2.36GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 16- to 26-Year-Old Females (Lot 1)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Males (Lot 1) · ANOVA · p = < 0.001 (one-sided tests of non-inferiority conducted at the alpha=0.025 level; model with a response of log individual titers and a fixed effect for comparison group) · Gmt ratio: 2.62 · 95% CI 2.27 to 3.03GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 16- to 26-Year-Old Females (Lot 1)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Males (Lot 1) · ANOVA · p = < 0.001 (one-sided tests of non-inferiority conducted at the alpha=0.025 level; model with a response of log individual titers and a fixed effect for comparison group) · Gmt ratio: 2.22 · 95% CI 1.97 to 2.51GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 16- to 26-Year-Old Females (Lot 1)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Males (Lot 1) · ANOVA · p = < 0.001 (one-sided tests of non-inferiority conducted at the alpha=0.025 level; model with a response of log individual titers and a fixed effect for comparison group) · Gmt ratio: 2.18 · 95% CI 1.93 to 2.45GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 16- to 26-Year-Old Females (Lot 1)
PrimaryBase Study: GMTs for Each of the HPV Types Contained in the Vaccine (9- to 15-Year-Old Males [Lot 1] and 16- to 26-Year-Old Females [Lot 1])

Serum antibody titers for HPV VLPs, Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using a competitive luminex immunoassay (cLIA). Titers were reported in milli Merck Units/mL.

Time frame:
4 weeks post-vaccination 3 (Month 7)
Reported as:
Geometric mean · milli Merck Units/mL
Base Study: GMTs for Each of the HPV Types Contained in the Vaccine (9- to 15-Year-Old Males [Lot 1] and 16- to 26-Year-Old Females [Lot 1])
milli Merck Units/mLBase Study: 9- to 15-Year-Old Males (Lot 1)Base Study: 16- to 26-Year-Old Females (Lot 1)
Anti-HPV 62084.7 (1944.0 to 2235.7)900.8 (822.3 to 986.9)
Anti-HPV 111487.1 (1386.5 to 1595.0)706.6 (645.2 to 773.8)
Anti-HPV 168628.9 (8065.9 to 9231.3)3522.6 (3223.5 to 3849.5)
Anti-HPV 182822.8 (2602.8 to 3061.5)882.7 (795.4 to 979.5)
Anti-HPV 312221.2 (2056.1 to 2399.5)753.9 (682.5 to 832.7)
Anti-HPV 331198.7 (1117.1 to 1286.2)466.8 (426.9 to 510.3)
Anti-HPV 45907.0 (830.2 to 991.0)272.2 (243.8 to 303.9)
Anti-HPV 521037.8 (964.4 to 1116.9)419.6 (381.4 to 461.5)
Anti-HPV 581567.7 (1460.2 to 1683.1)590.5 (538.2 to 647.9)
Statistical analysis
  • Base Study: 9- to 15-Year-Old Males (Lot 1) vs Base Study: 16- to 26-Year-Old Females (Lot 1) · ANOVA · p = < 0.001 (one-sided tests of non-inferiority conducted at the alpha=0.025 level; model with a response of log individual titers and a fixed effect for comparison group) · Gmt ratio: 2.31 · 95% CI 2.07 to 2.59GMT ratio = GMT for 9- to 15-Year-Old males (Lot 1) divided by GMT for 16- to 26-Year-Old Females (Lot 1)
  • Base Study: 9- to 15-Year-Old Males (Lot 1) vs Base Study: 16- to 26-Year-Old Females (Lot 1) · ANOVA · p = < 0.001 (one-sided tests of non-inferiority conducted at the alpha=0.025 level; model with a response of log individual titers and a fixed effect for comparison group) · Gmt ratio: 2.10 · 95% CI 1.88 to 2.36GMT ratio = GMT for 9- to 15-Year-Old Males (Lot 1) divided by GMT for 16- to 26-Year-Old Females (Lot 1)
  • Base Study: 9- to 15-Year-Old Males (Lot 1) vs Base Study: 16- to 26-Year-Old Females (Lot 1) · ANOVA · p = < 0.001 (one-sided tests of non-inferiority conducted at the alpha=0.025 level; model with a response of log individual titers and a fixed effect for comparison group) · Gmt ratio: 2.45 · 95% CI 2.19 to 2.74GMT ratio = GMT for 9- to 15-Year-Old Males (Lot 1) divided by GMT for 16- to 26-Year-Old Females (Lot 1)
  • Base Study: 9- to 15-Year-Old Males (Lot 1) vs Base Study: 16- to 26-Year-Old Females (Lot 1) · ANOVA · p = < 0.001 (one-sided tests of non-inferiority conducted at the alpha=0.025 level; model with a response of log individual titers and a fixed effect for comparison group) · Gmt ratio: 3.20 · 95% CI 2.80 to 3.65GMT ratio = GMT for 9- to 15-Year-Old Males (Lot 1) divided by GMT for 16- to 26-Year-Old Females (Lot 1)
  • Base Study: 9- to 15-Year-Old Males (Lot 1) vs Base Study: 16- to 26-Year-Old Females (Lot 1) · ANOVA · p = < 0.001 (one-sided tests of non-inferiority conducted at the alpha=0.025 level; model with a response of log individual titers and a fixed effect for comparison group) · Gmt ratio: 2.95 · 95% CI 2.60 to 3.34GMT ratio = GMT for 9- to 15-Year-Old Males (Lot 1) divided by GMT for 16- to 26-Year-Old Females (Lot 1)
  • Base Study: 9- to 15-Year-Old Males (Lot 1) vs Base Study: 16- to 26-Year-Old Females (Lot 1) · ANOVA · p = < 0.001 (one-sided tests of non-inferiority conducted at the alpha=0.025 level; model with a response of log individual titers and a fixed effect for comparison group) · Gmt ratio: 2.57 · 95% CI 2.29 to 2.88GMT ratio = GMT for 9- to 15-Year-Old Males (Lot 1) divided by GMT for 16- to 26-Year-Old Females (Lot 1)
  • Base Study: 9- to 15-Year-Old Males (Lot 1) vs Base Study: 16- to 26-Year-Old Females (Lot 1) · ANOVA · p = < 0.001 (one-sided tests of non-inferiority conducted at the alpha=0.025 level; model with a response of log individual titers and a fixed effect for comparison group) · Gmt ratio: 3.33 · 95% CI 2.89 to 3.84GMT ratio = GMT for 9- to 15-Year-Old Males (Lot 1) divided by GMT for 16- to 26-Year-Old Females (Lot 1)
  • Base Study: 9- to 15-Year-Old Males (Lot 1) vs Base Study: 16- to 26-Year-Old Females (Lot 1) · ANOVA · p = < 0.001 (one-sided tests of non-inferiority conducted at the alpha=0.025 level; model with a response of log individual titers and a fixed effect for comparison group) · Gmt ratio: 2.47 · 95% CI 2.19 to 2.79GMT ratio = GMT for 9- to 15-Year-Old Males (Lot 1) divided by GMT for 16- to 26-Year-Old Females (Lot 1)
  • Base Study: 9- to 15-Year-Old Males (Lot 1) vs Base Study: 16- to 26-Year-Old Females (Lot 1) · ANOVA · p = < 0.001 (one-sided tests of non-inferiority conducted at the alpha=0.025 level; model with a response of log individual titers and a fixed effect for comparison group) · Gmt ratio: 2.66 · 95% CI 2.37 to 2.98GMT ratio = GMT for 9- to 15-Year-Old Males (Lot 1) divided by GMT for 16- to 26-Year-Old Females (Lot 1)
PrimaryBase Study: GMTs for Each of the HPV Types Contained in the Vaccine (Lot Consistency Study)

Serum antibody titers for HPV VLPs, Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using cLIA. Titers were reported in milli Merck Units/mL.

Time frame:
4 weeks post-vaccination 3 (Month 7)
Reported as:
Geometric mean · milli Merck Units/mL
Base Study: GMTs for Each of the HPV Types Contained in the Vaccine (Lot Consistency Study)
milli Merck Units/mLBase Study: 9- to 15-Year-Old Females (Lot 1)Base Study: 9- to 15-Year-Old Females (Lot 2)Base Study: 9- to 15-Year-Old Females (Lot 3)
Anti-HPV 61715.4 (1588.7 to 1852.2)1763.3 (1635.4 to 1901.3)1659.9 (1540.3 to 1788.7)
Anti-HPV 111295.1 (1197.8 to 1400.3)1311.7 (1214.9 to 1416.3)1232.0 (1141.7 to 1329.5)
Anti-HPV 166979.8 (6476.1 to 7522.8)7292.9 (6772.7 to 7853.1)6948.2 (6458.7 to 7474.9)
Anti-HPV 182153.7 (1970.9 to 2353.5)2134.1 (1955.6 to 2329.0)1966.6 (1804.3 to 2143.5)
Anti-HPV 311891.6 (1738.5 to 2058.2)1867.8 (1719.3 to 2029.1)1879.0 (1731.0 to 2039.6)
Anti-HPV 33980.4 (909.2 to 1057.2)922.7 (856.2 to 994.4)931.1 (865.0 to 1002.3)
Anti-HPV 45714.4 (650.1 to 785.0)827.7 (754.1 to 908.5)678.4 (619.0 to 743.6)
Anti-HPV 52932.9 (860.8 to 1011.0)1007.9 (931.0 to 1091.2)971.2 (898.1 to 1050.3)
Anti-HPV 581286.7 (1190.0 to 1391.3)1344.9 (1244.6 to 1453.3)1208.1 (1119.6 to 1303.6)
Statistical analysis
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Females (Lot 2) · Gmt ratio: 0.97 · 95% CI 0.88 to 1.08GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 2)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Females (Lot 3) · Gmt ratio: 1.03 · 95% CI 0.93 to 1.16GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 3)
  • Base Study: 9- to 15-Year-Old Females (Lot 2) vs Base Study: 9- to 15-Year-Old Females (Lot 3) · Gmt ratio: 1.06 · 95% CI 0.95 to 1.19GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 2) divided by GMT for 9- to 15-Year-Old Females (Lot 3)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Females (Lot 2) · Gmt ratio: 1.00 · 95% CI 0.90 to 1.11GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 2)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Females (Lot 3) · Gmt ratio: 1.07 · 95% CI 0.95 to 1.20GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 3)
  • Base Study: 9- to 15-Year-Old Females (Lot 2) vs Base Study: 9- to 15-Year-Old Females (Lot 3) · Gmt ratio: 1.07 · 95% CI 0.95 to 1.20GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 2) divided by GMT for 9- to 15-Year-Old Females (Lot 3)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Females (Lot 2) · Gmt ratio: 0.96 · 95% CI 0.86 to 1.06GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 2)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Females (Lot 3) · Gmt ratio: 1.00 · 95% CI 0.90 to 1.12GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 3)
  • Base Study: 9- to 15-Year-Old Females (Lot 2) vs Base Study: 9- to 15-Year-Old Females (Lot 3) · Gmt ratio: 1.05 · 95% CI 0.94 to 1.17GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 2) divided by GMT for 9- to 15-Year-Old Females (Lot 3)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Females (Lot 2) · Gmt ratio: 1.00 · 95% CI 0.89 to 1.14GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 2)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Females (Lot 3) · Gmt ratio: 1.11 · 95% CI 0.98 to 1.26GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 3)
  • Base Study: 9- to 15-Year-Old Females (Lot 2) vs Base Study: 9- to 15-Year-Old Females (Lot 3) · Gmt ratio: 1.11 · 95% CI 0.97 to 1.26GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 2) divided by GMT for 9- to 15-Year-Old Females (Lot 3)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Females (Lot 2) · Gmt ratio: 1.00 · 95% CI 0.89 to 1.13GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 2)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Females (Lot 3) · Gmt ratio: 1.02 · 95% CI 0.91 to 1.16GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 3)
  • Base Study: 9- to 15-Year-Old Females (Lot 2) vs Base Study: 9- to 15-Year-Old Females (Lot 3) · Gmt ratio: 1.02 · 95% CI 0.90 to 1.15GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 2) divided by GMT for 9- to 15-Year-Old Females (Lot 3)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Females (Lot 2) · Gmt ratio: 1.05 · 95% CI 0.94 to 1.16GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 2)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Females (Lot 3) · Gmt ratio: 1.05 · 95% CI 0.94 to 1.17GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 3)
  • Base Study: 9- to 15-Year-Old Females (Lot 2) vs Base Study: 9- to 15-Year-Old Females (Lot 3) · Gmt ratio: 1.01 · 95% CI 0.90 to 1.12GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 2) divided by GMT for 9- to 15-Year-Old Females (Lot 3)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Females (Lot 2) · Gmt ratio: 0.84 · 95% CI 0.73 to 0.95GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 2)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Females (Lot 3) · Gmt ratio: 1.04 · 95% CI 0.91 to 1.18GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 3)
  • Base Study: 9- to 15-Year-Old Females (Lot 2) vs Base Study: 9- to 15-Year-Old Females (Lot 3) · Gmt ratio: 1.24 · 95% CI 1.08 to 1.42GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 2) divided by GMT for 9- to 15-Year-Old Females (Lot 3)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Females (Lot 2) · Gmt ratio: 0.92 · 95% CI 0.83 to 1.03GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 2)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Females (Lot 3) · Gmt ratio: 0.95 · 95% CI 0.85 to 1.07GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 3)
  • Base Study: 9- to 15-Year-Old Females (Lot 2) vs Base Study: 9- to 15-Year-Old Females (Lot 3) · Gmt ratio: 1.03 · 95% CI 0.92 to 1.16GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 2) divided by GMT for 9- to 15-Year-Old Females (Lot 3)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Females (Lot 2) · Gmt ratio: 0.95 · 95% CI 0.86 to 1.06GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 2)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Females (Lot 3) · Gmt ratio: 1.07 · 95% CI 0.96 to 1.20GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 1) divided by GMT for 9- to 15-Year-Old Females (Lot 3)
  • Base Study: 9- to 15-Year-Old Females (Lot 2) vs Base Study: 9- to 15-Year-Old Females (Lot 3) · Gmt ratio: 1.12 · 95% CI 1.00 to 1.26GMT ratio = GMT for 9- to 15-Year-Old Females (Lot 2) divided by GMT for 9- to 15-Year-Old Females (Lot 3)
PrimaryBase Study: Percentage of Participants With Injection Site Adverse Experiences (AEs)

An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine was also an AE. AEs such as redness, swelling, and pain/tenderness/soreness at the injection site were recorded.

Time frame:
Up to 5 days after any vaccination
Reported as:
Number · Percentage of Participants
Base Study: Percentage of Participants With Injection Site Adverse Experiences (AEs)
Percentage of Participants9- to 15-Year-Old Females (Lots 1, 2 or 3)Base Study: 9- to 15-Year-Old Males (Lot 1)Base Study: 16- to 26-Year-Old Females (Lot 1)
Base Study: Percentage of Participants With Injection Site Adverse Experiences (AEs)81.972.885.4
PrimaryBase Study: Percentage of Participants With Systemic AEs

An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine was also an AE. Systemic AEs were those not categorized as injection-site AEs.

Time frame:
Up to 15 days after any vaccination
Reported as:
Number · Percentage of Participants
Base Study: Percentage of Participants With Systemic AEs
Percentage of Participants9- to 15-Year-Old Females (Lots 1, 2 or 3)Base Study: 9- to 15-Year-Old Males (Lot 1)Base Study: 16- to 26-Year-Old Females (Lot 1)
Base Study: Percentage of Participants With Systemic AEs45.041.857.1
PrimaryBase Study: Percentage of Participants With Body Temperature ≥100.0°F (≥37.8ºC)

Participants collected their oral body temperature in the evening of their vaccination day and at the same time each day thereafter for 4 days. The maximum body temperature obtained within 5 days of any of the 3 vaccinations was recorded. The percentage of participants who had at least 1 oral body temperature reading that was ≥100.0°F (≥37.8ºC) was summarized.

Time frame:
Up to 5 days after any vaccination
Reported as:
Number · Percentage of Participants
Base Study: Percentage of Participants With Body Temperature ≥100.0°F (≥37.8ºC)
Percentage of Participants9- to 15-Year-Old Females (Lots 1, 2, or 3)Base Study: 9- to 15-Year-Old Males (Lot 1)Base Study: 16- to 26-Year-Old Females (Lot 1)
Base Study: Percentage of Participants With Body Temperature ≥100.0°F (≥37.8ºC)8.410.08.4
SecondaryBase Study: Percentage of Participants Who Seroconvert to Each of the HPV Types Contained in the Vaccine (9- to 15-Year-Old Females [Lot 1] and 16- to 26-Year-Old Females [Lot 1])

Serum antibody titers for HPV virus-like particles (VLPs), Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using cLIA. The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30, HPV Type 11: ≥16; HPV Type 16: ≥20, HPV Type 18: ≥24, HPV Type 31: ≥10, HPV Type 33: ≥8, HPV Type 45: ≥8, HPV Type 52: ≥8, and HPV Type 58: ≥8.

Time frame:
4 weeks post-vaccination 3 (Month 7)
Reported as:
Number · Percentage of Participants
Base Study: Percentage of Participants Who Seroconvert to Each of the HPV Types Contained in the Vaccine (9- to 15-Year-Old Females [Lot 1] and 16- to 26-Year-Old Females [Lot 1])
Percentage of ParticipantsBase Study: 9- to 15-Year-Old Females (Lot 1)Base Study: 9- to 15-Year-Old Males (Lot 1)
Anti-HPV 6 cLIA ≥30 mMU/mL99.8 (98.9 to 100)99.7 (98.3 to 100)
Anti-HPV 11 cLIA ≥16 mMU/mL100 (99.3 to 100.0)100 (98.9 to 100.0)
Anti-HPV 16 cLIA ≥20 mMU/mL100 (99.3 to 100.0)100 (98.9 to 100.0)
Anti-HPV 18 cLIA ≥24 mMU/mL99.8 (99.0 to 100.0)99.7 (98.4 to 100.0)
Anti-HPV 31 cLIA ≥10 mMU/mL100.0 (99.3 to 100.0)99.7 (98.4 to 100.0)
Anti-HPV 33 cLIA ≥8 mMU/mL100.0 (99.3 to 100.0)99.7 (98.4 to 100.0)
Anti-HPV 45 cLIA ≥8 mMU/mL99.8 (99.0 to 100.0)99.5 (98.1 to 99.9)
Anti-HPV 52 cLIA ≥8 mMU/mL100.0 (99.3 to 100.0)99.7 (98.4 to 100.0)
Anti-HPV 58 cLIA ≥8 mMU/mL100.0 (99.3 to 100.0)100.0 (98.9 to 100.0)
Statistical analysis
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Males (Lot 1) · Miettinen and Nurminen · p = < 0.001 · Percentage point difference: 0.1 · 95% CI -0.8 to 1.5Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 16- to 26-Year-Old Females (Lot 1)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Males (Lot 1) · Miettinen and Nurminen · p = < 0.001 · Percentage point difference: 0.0 · 95% CI -0.7 to 1.2Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 16- to 26-Year-Old Females (Lot 1)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Males (Lot 1) · Miettinen and Nurminen · p = < 0.001 · Percentage point difference: 0.0 · 95% CI -0.7 to 1.2Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 16- to 26-Year-Old Females (Lot 1)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Males (Lot 1) · Miettinen and Nurminen · p = < 0.001 · Percentage point difference: 0.1 · 95% CI -0.8 to 1.5Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 16- to 26-Year-Old Females (Lot 1)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Males (Lot 1) · Miettinen and Nurminen · p = < 0.001 · Percentage point difference: 0.3 · 95% CI -0.4 to 1.7Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 16- to 26-Year-Old Females (Lot 1)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Males (Lot 1) · Miettinen and Nurminen · p = < 0.001 · Percentage point difference: 0.3 · 95% CI -0.4 to 1.6Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 16- to 26-Year-Old Females (Lot 1)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Males (Lot 1) · Miettinen and Nurminen · p = < 0.001 · Percentage point difference: 0.4 · 95% CI -0.6 to 1.8Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 16- to 26-Year-Old Females (Lot 1)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Males (Lot 1) · Miettinen and Nurminen · p = < 0.001 · Percentage point difference: 0.3 · 95% CI -0.4 to 1.7Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 16- to 26-Year-Old Females (Lot 1)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Males (Lot 1) · Miettinen and Nurminen · p = < 0.001 · Percentage point difference: 0.0 · 95% CI -0.7 to 1.2Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 16- to 26-Year-Old Females (Lot 1)
SecondaryBase Study: Percentage of Participants Who Seroconvert to Each of the HPV Types Contained in the Vaccine (9- to 15-Year-Old Males [Lot 1] Versus 16- to 26-Year-Old Females [Lot 1])

Serum antibody titers for HPV VLPs, Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using cLIA. The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30, HPV Type 11: ≥16; HPV Type 16: ≥20, HPV Type 18: ≥24, HPV Type 31: ≥10, HPV Type 33: ≥8, HPV Type 45: ≥8, HPV Type 52: ≥8, and HPV Type 58: ≥8.

Time frame:
4 weeks post-vaccination 3 (Month 7)
Reported as:
Number · Percentage of Participants
Base Study: Percentage of Participants Who Seroconvert to Each of the HPV Types Contained in the Vaccine (9- to 15-Year-Old Males [Lot 1] Versus 16- to 26-Year-Old Females [Lot 1])
Percentage of ParticipantsBase Study: 9- to 15-Year-Old Males (Lot 1)Base Study: 16- to 26-Year-Old Females (Lot 1)
Anti-HPV 6 cLIA ≥30 mMU/mL99.8 (99.0 to 100.0)99.7 (98.3 to 100.0)
Anti-HPV 11 cLIA ≥16 mMU/mL100.0 (99.3 to 100.0)100.0 (98.9 to 100.0)
Anti-HPV 16 cLIA ≥20 mMU/mL100.0 (99.4 to 100.0)100.0 (98.9 to 100.0)
Anti-HPV 18 cLIA ≥24 mMU/mL100.0 (99.4 to 100.0)99.7 (98.4 to 100.0)
Anti-HPV 31 cLIA ≥10 mMU/mL100.0 (99.3 to 100.0)99.7 (98.4 to 100.0)
Anti-HPV 33 cLIA ≥8 mMU/mL100.0 (99.4 to 100.0)99.7 (98.4 to 100.0)
Anti-HPV 45 cLIA ≥8 mMU/mL100.0 (99.4 to 100.0)99.5 (98.1 to 99.9)
Anti-HPV 52 cLIA ≥8 mMU/mL100.0 (99.4 to 100.0)99.7 (98.4 to 100.0)
Anti-HPV 58 cLIA ≥8 mMU/mL100.0 (99.4 to 100.0)100.0 (98.9 to 100.0)
Statistical analysis
  • Base Study: 9- to 15-Year-Old Males (Lot 1) vs Base Study: 16- to 26-Year-Old Females (Lot 1) · Miettinen and Nurminen · p = < 0.001 · Percentage point difference: 0.1 · 95% CI -0.7 to 1.5Percentage Point Difference = 9- to 15-Year-Old Males (Lot 1) minus 16- to 26-Year-Old Females (Lot 1)
  • Base Study: 9- to 15-Year-Old Males (Lot 1) vs Base Study: 16- to 26-Year-Old Females (Lot 1) · Miettinen and Nurminen · p = < 0.001 · Percentage point difference: 0.0 · 95% CI -0.7 to 1.2Percentage Point Difference = 9- to 15-Year-Old Males (Lot 1) minus 16- to 26-Year-Old Females (Lot 1)
  • Base Study: 9- to 15-Year-Old Males (Lot 1) vs Base Study: 16- to 26-Year-Old Females (Lot 1) · Miettinen and Nurminen · p = < 0.001 · Percentage point difference: 0.0 · 95% CI -0.7 to 1.2Percentage Point Difference = 9- to 15-Year-Old Males (Lot 1) minus 16- to 26-Year-Old Females (Lot 1)
  • Base Study: 9- to 15-Year-Old Males (Lot 1) vs Base Study: 16- to 26-Year-Old Females (Lot 1) · Miettinen and Nurminen · p = < 0.001 · Percentage point difference: 0.3 · 95% CI -0.4 to 1.6Percentage Point Difference = 9- to 15-Year-Old Males (Lot 1) minus 16- to 26-Year-Old Females (Lot 1)
  • Base Study: 9- to 15-Year-Old Males (Lot 1) vs Base Study: 16- to 26-Year-Old Females (Lot 1) · Miettinen and Nurminen · p = < 0.001 · Percentage point difference: 0.3 · 95% CI -0.4 to 1.7Percentage Point Difference = 9- to 15-Year-Old Males (Lot 1) minus 16- to 26-Year-Old Females (Lot 1)
  • Base Study: 9- to 15-Year-Old Males (Lot 1) vs Base Study: 16- to 26-Year-Old Females (Lot 1) · Miettinen and Nurminen · p = < 0.001 · Percentage point difference: 0.3 · 95% CI -0.4 to 1.6Percentage Point Difference = 9- to 15-Year-Old Males (Lot 1) minus 16- to 26-Year-Old Females (Lot 1)
  • Base Study: 9- to 15-Year-Old Males (Lot 1) vs Base Study: 16- to 26-Year-Old Females (Lot 1) · Miettinen and Nurminen · p = < 0.001 · Percentage point difference: 0.5 · 95% CI -0.1 to 2.0Percentage Point Difference = 9- to 15-Year-Old Males (Lot 1) minus 16- to 26-Year-Old Females (Lot 1)
  • Base Study: 9- to 15-Year-Old Males (Lot 1) vs Base Study: 16- to 26-Year-Old Females (Lot 1) · Miettinen and Nurminen · p = < 0.001 · Percentage point difference: 0.3 · 95% CI -0.4 to 1.7Percentage Point Difference = 9- to 15-Year-Old Males (Lot 1) minus 16- to 26-Year-Old Females (Lot 1)
  • Base Study: 9- to 15-Year-Old Males (Lot 1) vs Base Study: 16- to 26-Year-Old Females (Lot 1) · Miettinen and Nurminen · p = < 0.001 · Percentage point difference: 0.0 · 95% CI -0.7 to 1.2Percentage Point Difference = 9- to 15-Year-Old Males (Lot 1) minus 16- to 26-Year-Old Females (Lot 1)
SecondaryBase Study: Percentage of Participants Who Seroconvert to Each of the HPV Types Contained in the Vaccine (Lot Consistency Study)

Serum antibody titers for HPV virus-like particles (VLPs), Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post- vaccination 3 using cLIA. The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30, HPV Type 11: ≥16; HPV Type 16: ≥20, HPV Type 18: ≥24, HPV Type 31: ≥10, HPV Type 33: ≥8, HPV Type 45: ≥8, HPV Type 52: ≥8, and HPV Type 58: ≥8.

Time frame:
4 weeks post-vaccination 3 (Month 7)
Reported as:
Number · Percentage of Participants
Base Study: Percentage of Participants Who Seroconvert to Each of the HPV Types Contained in the Vaccine (Lot Consistency Study)
Percentage of ParticipantsBase Study: 9- to 15-Year-Old Females (Lot 1)Base Study: 9- to 15-Year-Old Females (Lot 2)Base Study: 9- to 15-Year-Old Females (Lot 3)
HPV 6 cLIA ≥30 mMU/mL99.8 (98.9 to 100.0)99.8 (99.0 to 100.0)99.3 (98.1 to 99.8)
HPV 11 cLIA ≥16 mMU/mL100.0 (99.3 to 100.0)100.0 (99.3 to 100.0)99.6 (98.7 to 100.0)
HPV 16 cLIA ≥20 mMU/mL100.0 (99.3 to 100.0)100.0 (99.3 to 100.0)99.6 (98.7 to 100.0)
HPV 18 cLIA ≥24 mMU/mL99.8 (99.0 to 100.0)100.0 (99.3 to 100.0)99.6 (98.7 to 100.0)
HPV 31 cLIA ≥10 mMU/mL100.0 (99.3 to 100.0)100.0 (99.3 to 100.0)99.8 (99.0 to 100.0)
HPV 33 cLIA ≥8 mMU/mL100.0 (99.3 to 100.0)100.0 (99.3 to 100.0)99.6 (98.7 to 100.0)
HPV 45 cLIA ≥8 mMU/mL99.8 (99.0 to 100.0)100.0 (99.3 to 100.0)99.6 (98.7 to 100.0)
HPV 52 cLIA ≥8 mMU/mL100.0 (99.3 to 100.0)100.0 (99.3 to 100.0)99.6 (98.7 to 100.0)
HPV 58 cLIA ≥8 mMU/mL100.0 (99.3 to 100.0)100.0 (99.3 to 100.0)99.6 (98.7 to 100.0)
Statistical analysis
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Females (Lot 2) · Percentage point difference: 0.0 · 95% CI -0.9 to 0.9Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 2)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Females (Lot 3) · Percentage point difference: 0.5 · 95% CI -0.4 to 1.7Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 3)
  • Base Study: 9- to 15-Year-Old Females (Lot 2) vs Base Study: 9- to 15-Year-Old Females (Lot 3) · Percentage point difference: 0.6 · 95% CI -0.4 to 1.7Percentage Point Difference = 9- to 15-Year-Old Females (Lot 2) minus 9- to 15-Year-Old Females (Lot 3)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Females (Lot 2) · Percentage point difference: 0.0 · 95% CI -0.7 to 0.7Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 2)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Females (Lot 3) · Percentage point difference: 0.4 · 95% CI -0.4 to 1.3Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 3)
  • Base Study: 9- to 15-Year-Old Females (Lot 2) vs Base Study: 9- to 15-Year-Old Females (Lot 3) · Percentage point difference: 0.4 · 95% CI -0.4 to 1.3Percentage Point Difference = 9- to 15-Year-Old Females (Lot 2) minus 9- to 15-Year-Old Females (Lot 3)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Females (Lot 2) · Percentage point difference: 0.0 · 95% CI -0.7 to 0.7Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 2)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Females (Lot 3) · Percentage point difference: 0.4 · 95% CI -0.4 to 1.3Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 3)
  • Base Study: 9- to 15-Year-Old Females (Lot 2) vs Base Study: 9- to 15-Year-Old Females (Lot 3) · Percentage point difference: 0.4 · 95% CI -0.4 to 1.3Percentage Point Difference = 9- to 15-Year-Old Females (Lot 2) minus 9- to 15-Year-Old Females (Lot 3)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Females (Lot 2) · Percentage point difference: -0.2 · 95% CI -1.1 to 0.5Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 2)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Females (Lot 3) · Percentage point difference: 0.2 · 95% CI -0.7 to 1.1Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 3)
  • Base Study: 9- to 15-Year-Old Females (Lot 2) vs Base Study: 9- to 15-Year-Old Females (Lot 3) · Percentage point difference: 0.4 · 95% CI -0.4 to 1.3Percentage Point Difference = 9- to 15-Year-Old Females (Lot 2) minus 9- to 15-Year-Old Females (Lot 3)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Females (Lot 2) · Percentage point difference: 0.0 · 95% CI -0.7 to 0.7Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 2)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Females (Lot 3) · Percentage point difference: 0.2 · 95% CI -0.6 to 1.0Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 3)
  • Base Study: 9- to 15-Year-Old Females (Lot 2) vs Base Study: 9- to 15-Year-Old Females (Lot 3) · Percentage point difference: 0.2 · 95% CI -0.5 to 1.0Percentage Point Difference = 9- to 15-Year-Old Females (Lot 2) minus 9- to 15-Year-Old Females (Lot 3)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Females (Lot 2) · Percentage point difference: 0.0 · 95% CI -0.7 to 0.7Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 2)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Females (Lot 3) · Percentage point difference: 0.4 · 95% CI -0.4 to 1.3Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 3)
  • Base Study: 9- to 15-Year-Old Females (Lot 2) vs Base Study: 9- to 15-Year-Old Females (Lot 3) · Percentage point difference: 0.4 · 95% CI -0.4 to 1.3Percentage Point Difference = 9- to 15-Year-Old Females (Lot 2) minus 9- to 15-Year-Old Females (Lot 3)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Females (Lot 2) · Percentage point difference: -0.2 · 95% CI -1.1 to 0.5Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 2)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Females (Lot 3) · Percentage point difference: 0.2 · 95% CI -0.7 to 1.1Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 3)
  • Base Study: 9- to 15-Year-Old Females (Lot 2) vs Base Study: 9- to 15-Year-Old Females (Lot 3) · Percentage point difference: 0.4 · 95% CI -0.4 to 1.3Percentage Point Difference = 9- to 15-Year-Old Females (Lot 2) minus 9- to 15-Year-Old Females (Lot 3)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Females (Lot 2) · Percentage point difference: 0.0 · 95% CI -0.7 to 0.7Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 2)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Females (Lot 3) · Percentage point difference: 0.3 · 95% CI -0.4 to 1.3Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 3)
  • Base Study: 9- to 15-Year-Old Females (Lot 2) vs Base Study: 9- to 15-Year-Old Females (Lot 3) · Percentage point difference: 0.4 · 95% CI -0.4 to 1.3Percentage Point Difference = 9- to 15-Year-Old Females (Lot 2) minus 9- to 15-Year-Old Females (Lot 3)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Females (Lot 2) · Percentage point difference: 0.0 · 95% CI -0.7 to 0.7Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 2)
  • Base Study: 9- to 15-Year-Old Females (Lot 1) vs Base Study: 9- to 15-Year-Old Females (Lot 3) · Percentage point difference: 0.4 · 95% CI -0.4 to 1.3Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 3)
  • Base Study: 9- to 15-Year-Old Females (Lot 2) vs Base Study: 9- to 15-Year-Old Females (Lot 3) · Percentage point difference: 0.4 · 95% CI -0.4 to 1.3Percentage Point Difference = 9- to 15-Year-Old Females (Lot 2) minus 9- to 15-Year-Old Females (Lot 3)
PrimaryExtension Study: GMTs For Each of the HPV Types Contained in the Vaccine

Serum antibody titers (milli Merck Units/mL) measured by cLIA to each of the 9vHPV types were assessed. Per protocol, the extension study included data from 9- to 15-year-old females regardless of lot administered.

Time frame:
Up to ~Month 126
Reported as:
Geometric mean · milli Merck Units/mL
Extension Study: GMTs For Each of the HPV Types Contained in the Vaccine
milli Merck Units/mLExtension Study: 9- to 15-Year-Old FemalesExtension Study: 9- to 15-Year-Old Males
Anti-HPV 6122.3 (111.1 to 134.7)129.5 (112.5 to 149.1)
Anti-HPV 1180.2 (72.5 to 88.8)91.0 (78.4 to 105.6)
Anti-HPV 16403.0 (357.3 to 454.5)414.3 (353.8 to 485.3)
Anti-HPV 18128.1 (116.7 to 140.7)148.4 (130.2 to 169.2)
Anti-HPV 31108.9 (97.6 to 121.6)128.6 (111.2 to 148.8)
Anti-HPV 3359.2 (53.7 to 65.2)69.6 (60.7 to 79.7)
Anti-HPV 4542.1 (37.7 to 47.1)49.8 (43.0 to 57.8)
Anti-HPV 5255.3 (50.5 to 60.6)59.6 (52.0 to 68.4)
Anti-HPV 5876.5 (69.2 to 84.6)90.5 (78.4 to 104.6)
PrimaryExtension Study: Percentage of Participants Who Are Seropositive to Each of the HPV Types Contained in the Vaccine

Serum antibody titers for HPV VLPs Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined and reported in milli Merck Units/mL. The percentage of participants seropositive to each HPV type was reported. Per protocol, the extension study included data from 9- to 15-year-old females regardless of lot administered.

Time frame:
Up to ~Month 126
Reported as:
Number · Percentage of Participants
Extension Study: Percentage of Participants Who Are Seropositive to Each of the HPV Types Contained in the Vaccine
Percentage of ParticipantsExtension Study: 9- to 15-Year-Old FemalesExtension Study: 9- to 15-Year-Old Males
Anti-HPV 682.7 (78.3 to 86.6)84.1 (77.8 to 89.2)
Anti-HPV 1185.2 (81.0 to 88.9)87.0 (81.0 to 91.7)
Anti-HPV 1697.3 (95.0 to 98.8)98.3 (95.0 to 99.6)
Anti-HPV 1880.1 (75.5 to 84.2)83.7 (77.4 to 88.8)
Anti-HPV 3190.1 (86.4 to 93.0)92.7 (87.8 to 96.0)
Anti-HPV 3385.2 (81.0 to 88.8)89.3 (83.8 to 93.4)
Anti-HPV 4581.8 (77.2 to 85.9)92.3 (87.2 to 95.8)
Anti-HPV 5288.2 (84.4 to 91.4)89.2 (83.7 to 93.4)
Anti-HPV 5896.5 (94.0 to 98.2)97.1 (93.5 to 99.1)
SecondaryExtension Study: Combined Incidence of HPV 6/11/16/18/31/33/45/52/58-Related Persistent Infection in Females

Persistent infection is when a participant is positive by polymerase chain reaction (PCR) for the same HPV type in cervicovaginal/external genital swabs or tissue specimens collected at consecutive visits at least 6 months (+/-1 month visit window) apart. Incidence was estimated as cases per 10,000 person-years. Person-years follow-up was from beginning of long-term follow-up or when a study participant reached 16 years of age, whichever came later. Per protocol, the extension study included 9- to 15-year-old females regardless of lot administered.

Time frame:
Up to ~Month 126
Reported as:
Number · Cases per 10,000 person-years
Extension Study: Combined Incidence of HPV 6/11/16/18/31/33/45/52/58-Related Persistent Infection in Females
Cases per 10,000 person-yearsExtension Study: 9- to 15-Year-Old Females
Extension Study: Combined Incidence of HPV 6/11/16/18/31/33/45/52/58-Related Persistent Infection in Females52.4 ± 33.6
SecondaryExtension Study: Combined Incidence of HPV 6/11/16/18/31/33/45/52/58-Related Persistent Infection in Males

Persistent infection is when a participant is positive by PCR for the same HPV type in external genital swabs or tissue specimens collected at consecutive visits at least 6 months (+/-1 month visit window) apart. Incidence was estimated as cases per 10,000 person-years. Person-years follow-up was from beginning of long-term follow-up or when a study participant reached 16 years of age, whichever came later.

Time frame:
Up to ~Month 126
Reported as:
Number · Cases per 10,000 person-years
Extension Study: Combined Incidence of HPV 6/11/16/18/31/33/45/52/58-Related Persistent Infection in Males
Cases per 10,000 person-yearsExtension Study: 9- to 15-Year-Old Males
Extension Study: Combined Incidence of HPV 6/11/16/18/31/33/45/52/58-Related Persistent Infection in Males54.6 ± 21.9
SecondaryExtension Study: Combined Incidence of Cervical Intraepithelial Neoplasia, Vulvar Intraepithelial Neoplasia, Vaginal Intraepithelial Neoplasia, Genital Warts, and Cervical/Vulvar/Vaginal Cancers Related to HPV 6/11/16/18/31/33/45/52/58 in Females

The combined incidence of cervical intraepithelial neoplasia, vulvar intraepithelial neoplasia, vaginal intraepithelial neoplasia, genital warts, and cervical/vulvar/vaginal cancers, related to HPV 6/11/16/18/31/33/45/52/58 was assessed. This outcome measure was determined by clinical/pathologic criteria and positive PCR assay for HPV type. Incidence was estimated as cases per 10,000 person-years. Person-years follow-up was calculated starting from the beginning of the long-term follow-up study or the date when the study participant reached 16 years of age, whichever came later. Per protocol, the extension study included data from 9- to 15-year-old females regardless of lot administered.

Time frame:
Up to ~Month 126
Reported as:
Number · Cases per 10,000 person-years
Extension Study: Combined Incidence of Cervical Intraepithelial Neoplasia, Vulvar Intraepithelial Neoplasia, Vaginal Intraepithelial Neoplasia, Genital Warts, and Cervical/Vulvar/Vaginal Cancers Related to HPV 6/11/16/18/31/33/45/52/58 in Females
Cases per 10,000 person-yearsExtension Study: 9- to 15-Year-Old Females
Extension Study: Combined Incidence of Cervical Intraepithelial Neoplasia, Vulvar Intraepithelial Neoplasia, Vaginal Intraepithelial Neoplasia, Genital Warts, and Cervical/Vulvar/Vaginal Cancers Related to HPV 6/11/16/18/31/33/45/52/58 in Females2.2 ± 0.1
SecondaryExtension Study: Combined Incidence of Penile Intraepithelial Neoplasia, Penile/Perineal/Perianal Cancers and Genital Warts Related to HPV 6/11/16/18/31/33/45/52/58 in Males

The combined incidence of penile intraepithelial neoplasia, penile/perineal/perianal cancers, and genital warts related to HPV6/11/16/18/31/33/45/52/58 was assessed. This outcome measure was determined by clinical/pathologic criteria and positive PCR assay for HPV type. Incidence was estimated as cases per 10,000 person-years. For each study participant, person-years follow up was calculated starting from the beginning of the long-term follow-up study or the date when the study participant reached 16 years of age, whichever came later.

Time frame:
Up to ~Month 126
Reported as:
Number · Cases per 10,000 person-years
Extension Study: Combined Incidence of Penile Intraepithelial Neoplasia, Penile/Perineal/Perianal Cancers and Genital Warts Related to HPV 6/11/16/18/31/33/45/52/58 in Males
Cases per 10,000 person-yearsExtension Study: 9- to 15-Year-Old Males
Extension Study: Combined Incidence of Penile Intraepithelial Neoplasia, Penile/Perineal/Perianal Cancers and Genital Warts Related to HPV 6/11/16/18/31/33/45/52/58 in Males0.0 ± 0.0
SecondaryExtension Study: Percentage of Participants With Vaccine-Related or Procedure-Related Serious Adverse Events

A serious adverse event (SAE) included a death which resulted in the participant discontinuing the study, a serious adverse experience that was considered by an investigator who was a qualified physician to be possibly, probably, or definitely vaccine related or study procedure related. Per protocol, the extension study included data from 9- to 15-year-old females regardless of lot administered.

Time frame:
Up to ~Month 126
Reported as:
Number · Percentage of Participants
Extension Study: Percentage of Participants With Vaccine-Related or Procedure-Related Serious Adverse Events
Percentage of ParticipantsExtension Study: 9- to 15-Year-Old FemalesExtension Study: 9- to 15-Year-Old Males
Extension Study: Percentage of Participants With Vaccine-Related or Procedure-Related Serious Adverse Events0.00.0

Adverse events

Collected over Base Study: Up to ~12 months; Extension Study: Up to ~126 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Base Study: 9- to 15-Year-Old Females (Lot 1)0/648 (0%)6/643 (0.9%)538/643 (83.7%)
Base Study: 9- to 15-Year-Old Females (Lot 2)0/643 (0%)2/639 (0.3%)537/639 (84%)
Base Study: 9- to 15-Year-Old Females (Lot 3)0/644 (0%)8/641 (1.2%)554/641 (86.4%)
Base Study: 9- to 15-Year-Old Males (Lot 1)0/669 (0%)11/662 (1.7%)505/662 (76.3%)
Base Study: 16- to 26-Year-Old Females (Lot 1)0/470 (0%)15/466 (3.2%)404/466 (86.7%)
EXT1: 9- to 15-Year-Old Females1/1,604 (0.1%)2/1,604 (0.1%)0/1,604 (0%)
EXT1: 9- to 15-Year-Old Males0/568 (0%)0/568 (0%)0/568 (0%)
EXT2: 9- to 15-Year-Old Females1/971 (0.1%)3/971 (0.3%)0/971 (0%)
EXT2: 9- to 15-Year-Old Males0/301 (0%)0/301 (0%)0/301 (0%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventBase Study: 9- to 15-Year-Old Females (Lot 1)Base Study: 9- to 15-Year-Old Females (Lot 2)Base Study: 9- to 15-Year-Old Females (Lot 3)Base Study: 9- to 15-Year-Old Males (Lot 1)Base Study: 16- to 26-Year-Old Females (Lot 1)EXT1: 9- to 15-Year-Old FemalesEXT1: 9- to 15-Year-Old MalesEXT2: 9- to 15-Year-Old FemalesEXT2: 9- to 15-Year-Old Males
Abortion inducedSurgical and medical procedures0/6431/6390/6410/6625/4660/16040/5680/9710/301
AppendicitisInfections and infestations1/6431/6390/6413/6620/4660/16040/5680/9710/301
Abdominal painGastrointestinal disorders0/6430/6390/6410/6621/4660/16040/5680/9710/301
Biliary colicHepatobiliary disorders0/6430/6390/6410/6621/4660/16040/5680/9710/301
Urinary tract infectionInfections and infestations0/6430/6390/6410/6621/4660/16040/5680/9710/301
ConcussionInjury, poisoning and procedural complications0/6430/6391/6410/6621/4660/16040/5680/9710/301
Foot fractureInjury, poisoning and procedural complications0/6430/6390/6410/6621/4660/16040/5680/9710/301
Gun shot woundInjury, poisoning and procedural complications0/6430/6390/6410/6621/4660/16040/5680/9710/301
HeadacheNervous system disorders0/6430/6390/6410/6621/4660/16040/5680/9710/301
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/6430/6390/6410/6621/4660/16040/5680/9710/301
Most frequent other events
Most frequent other events
EventBase Study: 9- to 15-Year-Old Females (Lot 1)Base Study: 9- to 15-Year-Old Females (Lot 2)Base Study: 9- to 15-Year-Old Females (Lot 3)Base Study: 9- to 15-Year-Old Males (Lot 1)Base Study: 16- to 26-Year-Old Females (Lot 1)EXT1: 9- to 15-Year-Old FemalesEXT1: 9- to 15-Year-Old MalesEXT2: 9- to 15-Year-Old FemalesEXT2: 9- to 15-Year-Old Males
Injection site painGeneral disorders506/643513/639529/641465/662393/4660/16040/5680/9710/301
Injection site swellingGeneral disorders207/643237/639226/641173/662150/4660/16040/5680/9710/301
Injection site erythemaGeneral disorders184/643192/639195/641159/662132/4660/16040/5680/9710/301
HeadacheNervous system disorders120/643122/639113/64198/662106/4660/16040/5680/9710/301
PyrexiaGeneral disorders76/64357/63964/64184/66243/4660/16040/5680/9710/301

Baseline characteristics

Per protocol, baseline characteristics were analyzed in all participants randomized in the base study.

Age, Customized
Age, Customized(Participants)Base Study: 9- to 15-Year-Old Females (Lot 1)Base Study: 9- to 15-Year-Old Females (Lot 2)Base Study: 9- to 15-Year-Old Females (Lot 3)Base Study: 9- to 15-Year-Old Males (Lot 1)Base Study: 16- to 26-Year-Old Females (Lot 1)Total
9 to 12 years44043243245001754
13 to 15 years2082112122190850
16 to 26 years0000470470
Sex: Female, Male
Sex: Female, Male(Participants)Base Study: 9- to 15-Year-Old Females (Lot 1)Base Study: 9- to 15-Year-Old Females (Lot 2)Base Study: 9- to 15-Year-Old Females (Lot 3)Base Study: 9- to 15-Year-Old Males (Lot 1)Base Study: 16- to 26-Year-Old Females (Lot 1)Total
Female64864364404702405
Male0006690669
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Luxembourg A, Moreira ED Jr, Samakoses R, Kim KH, Sun X, Maansson R, Moeller E, Christiano S, Chen J. Phase III, randomized controlled trial in girls 9-15 years old to evaluate lot consistency of a novel nine-valent human papillomavirus L1 virus-like particle vaccine. Hum Vaccin Immunother. 2015;11(6):1306-12. doi: 10.1080/21645515.2015.1009819. PubMed 26086587 ↗
  • Van Damme P, Olsson SE, Block S, Castellsague X, Gray GE, Herrera T, Huang LM, Kim DS, Pitisuttithum P, Chen J, Christiano S, Maansson R, Moeller E, Sun X, Vuocolo S, Luxembourg A. Immunogenicity and Safety of a 9-Valent HPV Vaccine. Pediatrics. 2015 Jul;136(1):e28-39. doi: 10.1542/peds.2014-3745. PubMed 26101366 ↗
  • Moreira ED Jr, Block SL, Ferris D, Giuliano AR, Iversen OE, Joura EA, Kosalaraksa P, Schilling A, Van Damme P, Bornstein J, Bosch FX, Pils S, Cuzick J, Garland SM, Huh W, Kjaer SK, Qi H, Hyatt D, Martin J, Moeller E, Ritter M, Baudin M, Luxembourg A. Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical Trials. Pediatrics. 2016 Aug;138(2):e20154387. doi: 10.1542/peds.2015-4387. Epub 2016 Jul 15. PubMed 27422279 ↗
  • Olsson SE, Restrepo JA, Reina JC, Pitisuttithum P, Ulied A, Varman M, Van Damme P, Moreira ED Jr, Ferris D, Block S, Bautista O, Gallagher N, McCauley J, Luxembourg A. Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up. Papillomavirus Res. 2020 Dec;10:100203. doi: 10.1016/j.pvr.2020.100203. Epub 2020 Jul 11. PubMed 32659510 ↗
  • Garland SM, Pitisuttithum P, Ngan HYS, Cho CH, Lee CY, Chen CA, Yang YC, Chu TY, Twu NF, Samakoses R, Takeuchi Y, Cheung TH, Kim SC, Huang LM, Kim BG, Kim YT, Kim KH, Song YS, Lalwani S, Kang JH, Sakamoto M, Ryu HS, Bhatla N, Yoshikawa H, Ellison MC, Han SR, Moeller E, Murata S, Ritter M, Sawata M, Shields C, Walia A, Perez G, Luxembourg A. Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries. J Infect Dis. 2018 Jun 5;218(1):95-108. doi: 10.1093/infdis/jiy133. PubMed 29767739 ↗
  • Ruiz-Sternberg AM, Moreira ED Jr, Restrepo JA, Lazcano-Ponce E, Cabello R, Silva A, Andrade R, Revollo F, Uscanga S, Victoria A, Guevara AM, Luna J, Plata M, Dominguez CN, Fedrizzi E, Suarez E, Reina JC, Ellison MC, Moeller E, Ritter M, Shields C, Cashat M, Perez G, Luxembourg A. Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women. Papillomavirus Res. 2018 Jun;5:63-74. doi: 10.1016/j.pvr.2017.12.004. Epub 2017 Dec 19. PubMed 29269325 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2009 to primary completion in Apr 2011, 20 months.

Results were first posted in Jan 2015, 3 years 8 months after primary completion.

Of 46 industry-sponsored phase 3 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 55. This study's 20 months is below that.

Counting every sponsor, half of 99 studies reached it within 55 months; a quarter within 24 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2009
First posted
Jul 22, 2009
StartActual
Aug 27, 2009
Primary completionActual
Apr 30, 2011
CompletionActual
Apr 22, 2021
Results first posted
Jan 13, 2015
Last update
Oct 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00943722
Responsible party
Sponsor
First posted
Jul 22, 2009
Start date
Aug 27, 2009
Primary completion
Apr 30, 2011
Completion
Apr 22, 2021
Results posted
Jan 13, 2015
Last update
Oct 3, 2022

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Papillomavirus Recombinant Vaccine nonavalent

Start the discussion